SCHEMBL977752

SCHEMBL977752

Oc1ccc(C2(c3ccc(OCc4ccccn4)cc3)CCC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP10 Q53GL7 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ ESR1 P03372 2/20 0.47
▸ ESR2 Q92731 2/20 0.47
▸ HPGD P15428 1/20 0.45
▸ CYP1A2 P05177 2/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ ALOX5AP P20292 6/20 0.43
▸ LMNA P02545 1/20 0.41
▸ PTGS1 P23219 1/20 0.41
▸ SLC6A2 P23975 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ PTGS2 P35354 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL975580 0.86 PARP10 (0.57) PARP10KDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL975773 0.86 CYP1A2 (0.47) PARP10KDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL976155 0.86 MAPK14 (0.47) PARP10KDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL22874534 0.84 PARP10 (0.66) PARP10KDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL977042 0.84 PARP10 (0.57) PARP10KDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL974397 0.83 PARP10 (0.54) PARP10KDM4EALDH1A1SMN1; SMN2ALOX5AP
SCHEMBL976551 0.83 PARP10 (0.56) PARP10KDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL975447 0.82 PARP10 (0.53) PARP10SMN1; SMN2HPGD
SCHEMBL977680 0.82 MAPK14 (0.47) PARP10KDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL975521 0.82 CYP3A4 (0.45) PARP10KDM4EALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003815-A1 DIPHENYL SUBSTITUTED CYCLOALKANES MERCK & CO., INC. 2011-01-06 — — US disclosed
US-20110003815-A1 DIPHENYL SUBSTITUTED CYCLOALKANES MERCK & CO., INC. 2011-01-06 — — US disclosed
US-20110003815-A1 DIPHENYL SUBSTITUTED CYCLOALKANES MERCK & CO., INC. 2011-01-06 — — US disclosed
WO-2009048547-A1 DIPHENYL SUBSTITUTED CYCLOALKANES MERCK & CO., INC. (US) 2009-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003815-A1 DIPHENYL SUBSTITUTED CYCLOALKANES PTGIS, PTGS1, LTC4S PARP10 567/4885KDM4E 3639/4885ALDH1A1 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback